Mandaviya launches Bharat Biotech's nasal Covid vaccine


1 min read
Read later
Print
Share

New Delhi: Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday.

The world's first made-in-India intranasal vaccine was launched at Mandaviya's residence here.

The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's (DCGI) approval in November for restricted emergency use among adults as a heterologous booster dose.

According to a statement issued by Bharat Biotech earlier, 'iNCOVACC' is priced at Rs 800 for private markets and at Rs 325 for supplies to the government of India and state governments

iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, the Hyderabad-based vaccine maker had said.

Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule and as a heterologous booster dose for subjects who have previously received two doses of either Covishield or Covaxin.

PTI

Add Comment
Related Topics

Get daily updates from Mathrubhumi.com

Newsletter
Youtube
Telegram
Disclaimer: Kindly avoid objectionable, derogatory, unlawful and lewd comments, while responding to reports. Such comments are punishable under cyber laws. Please keep away from personal attacks. The opinions expressed here are the personal opinions of readers and not that of Mathrubhumi.

IN CASE YOU MISSED IT
modi, trudeau

1 min

India temporarily suspends visa services for Canadians until further notice

Sep 21, 2023


Rajya Sabha

2 min

Cutting across party lines, Rajya Sabha MPs support women's reservation bill

Sep 21, 2023


Vikram Lander

3 min

Will Chandrayaan-3 lander and rover wake up? ISRO to try to reestablish communication

Sep 21, 2023